Medicare Launches Temporary GLP-1 Bridge Program Covering Novo, Lilly Drugs
Medicare launches a temporary bridge program to cover GLP-1 drugs from Novo Nordisk and Eli Lilly, including Wegovy, Zepbound, and Foundayo, expanding access for obesity patients.
The Centers for Medicare & Medicaid Services (CMS) announced a temporary bridge program to cover GLP-1 drugs, including products from Novo Nordisk and Eli Lilly. The decision responds to rising demand for obesity treatments.
Program Details
The temporary program will cover:
- Novo Nordisk's Wegovy injections and tablets
- Eli Lilly's Zepbound KwikPen formulation and Foundayo tablets
The program aims to bridge coverage for eligible patients until a permanent coverage decision is made.
Company Stance
Both Novo Nordisk and Eli Lilly welcomed the decision, calling it a positive step toward improving access to obesity treatments. They confirmed readiness to collaborate with Medicare for smooth implementation.
Regulatory Context
The move follows years of advocacy by patient groups and physicians to expand Medicare coverage for weight-loss drugs. Previously, Medicare excluded obesity drugs from coverage.
Potential Financial Impact
Medicare has not disclosed the program's budget or duration. However, the decision is expected to significantly boost sales of the covered drugs, especially given the high demand for GLP-1 therapies.
Frequently Asked Questions
Found this useful? Share it